Get the Stockscreener App
25.96
0.36%
0.0703
Staar Surgical Co stock is traded at $25.96, with a volume of 914.34K.
It is up +0.36% in the last 24 hours and up +1.22% over the past month.
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.
See More
Previous Close:
$25.89
Open:
$26.17
24h Volume:
914.34K
Relative Volume:
0.81
Market Cap:
$1.27B
Revenue:
$224.45M
Net Income/Loss:
$-95.27M
P/E Ratio:
-13.45
EPS:
-1.93
Net Cash Flow:
$-43.74M
1W Performance:
+5.28%
1M Performance:
+1.22%
6M Performance:
+54.20%
1Y Performance:
+7.10%
1-Day Range:
$25.70
$26.17
1-Week Range:
$23.03
$26.18
52-Week Range:
$13.50
$30.81
Staar Surgical Co Stock (STAA) Company Profile
Name
Staar Surgical Co
Sector
Industry
Phone
(626) 303-7902
Address
1911 WALKER AVE, MONROVIA, CA
Compare STAA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STAA
Staar Surgical Co
|
25.70 | 1.28B | 224.45M | -95.27M | -43.74M | -1.93 |
|
ISRG
Intuitive Surgical Inc
|
563.76 | 197.40B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
196.57 | 55.76B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
80.06 | 38.93B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
243.81 | 35.90B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
WST
West Pharmaceutical Services Inc
|
267.69 | 19.36B | 2.96B | 487.70M | 344.00M | 6.6758 |
Staar Surgical Co Stock (STAA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-25 | Initiated | Wells Fargo | Equal Weight |
| Feb-12-25 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-12-25 | Downgrade | Jefferies | Buy → Hold |
| Feb-12-25 | Downgrade | Mizuho | Outperform → Neutral |
| Feb-12-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-15-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jun-11-24 | Upgrade | BTIG Research | Neutral → Buy |
| Mar-11-24 | Upgrade | Stifel | Hold → Buy |
| Dec-05-23 | Downgrade | Needham | Buy → Hold |
| Dec-04-23 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-15-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-03-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jun-07-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-17-23 | Initiated | Piper Sandler | Neutral |
| Feb-06-23 | Downgrade | BTIG Research | Buy → Neutral |
| Dec-28-22 | Reiterated | BTIG Research | Buy |
| Dec-08-22 | Initiated | Stifel | Hold |
| Nov-07-22 | Upgrade | Sidoti | Neutral → Buy |
| Oct-14-22 | Resumed | Stephens | Overweight |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Apr-08-22 | Initiated | Needham | Buy |
| Mar-28-22 | Upgrade | The Benchmark Company | Hold → Buy |
| Mar-18-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jul-09-21 | Initiated | Oppenheimer | Perform |
| Jan-19-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Oct-26-20 | Downgrade | Sidoti | Buy → Neutral |
| Aug-31-20 | Upgrade | Sidoti | Neutral → Buy |
| Aug-06-20 | Reiterated | The Benchmark Company | Buy |
| Jul-06-20 | Downgrade | Sidoti | Buy → Neutral |
| Jun-24-20 | Downgrade | BTIG Research | Buy → Neutral |
| Jun-15-20 | Initiated | Jefferies | Buy |
| Dec-04-19 | Initiated | BTIG Research | Buy |
| Sep-24-18 | Reiterated | The Benchmark Company | Buy |
| Aug-06-18 | Resumed | The Benchmark Company | Buy |
| Nov-20-17 | Reiterated | The Benchmark Company | Buy |
| Aug-14-17 | Reiterated | The Benchmark Company | Buy |
| Mar-03-17 | Reiterated | The Benchmark Company | Buy |
| May-18-16 | Upgrade | The Benchmark Company | Hold → Buy |
| Sep-10-13 | Resumed | The Benchmark Company | Buy |
| Feb-28-13 | Reiterated | The Benchmark Company | Buy |
| Nov-01-12 | Downgrade | Canaccord Genuity | Buy → Hold |
| Mar-02-12 | Initiated | Northland Securities | Outperform |
| Oct-25-11 | Reiterated | The Benchmark Company | Buy |
| Oct-12-10 | Initiated | Morgan Joseph | Buy |
| May-11-10 | Initiated | Benchmark | Buy |
View All
Staar Surgical Co Stock (STAA) Latest News
Midday Stock Roundup: Adagio Medical, Virgin Galactic Up - Orange County Business Journal
Broadwood sees $50/share path for STAAR Surgical as merger battle nears voting day - Investing.com India
Defender Capital to vote against STAAR Surgical sale to Alcon By Investing.com - Investing.com Nigeria
Defender Capital to vote against STAAR Surgical sale to Alcon - Investing.com India
STAAR urges stockholders to vote for Alcon merger amid proxy battle - Investing.com Nigeria
Broadwood urges shareholders to reject Alcon’s bid for STAAR - Investing.com
Big STAAR investor fights Alcon buyout, says shares should hit $50 - Stock Titan
STAAR Stockholders Have a Choice: Vote FOR Alcon’s Certain, Premium $30.75 Per Share Cash Offer or Bear the Downside Risk that Broadwood Has No Credible Plan to Create Stockholder Value | ALC Stock News - Stock Titan
Yunqi Capital Comments on Proxy Advisors' Updated Recommendations, Urges Shareholders to Continue to Back the Company's Standalone Trajectory - marketscreener.com
STAAR Surgical (NASDAQ: STAA) investor Yunqi Capital urges no vote on Alcon deal - Stock Titan
ISS recommends STAAR Surgical deal, but warns shareholders have reason to object - Investing.com
Yunqi Capital to vote against revised Alcon-STAAR merger offer By Investing.com - Investing.com South Africa
Yunqi Capital to vote against revised Alcon-STAAR merger offer - Investing.com
Yunqi Capital says remains opposed to STAAR’s proposed merger with Alcon - TipRanks
5.1% STAAR owner fights Alcon deal, arguing company is worth more - Stock Titan
STAAR Surgical (NASDAQ:STAA) Shares Gap UpTime to Buy? - MarketBeat
Alcon raises STAAR Surgical acquisition offer to $30.75 per share By Investing.com - Investing.com Nigeria
Alcon (NYSE: ALC) $30.75-per-share STAAR bid gains support from analysts and ISS - Stock Titan
Proxy firms raise concerns over STAAR Surgical’s proposed sale to Alcon - Investing.com Canada
Proxy firms raise concerns over STAAR Surgical’s proposed sale to Alcon By Investing.com - Investing.com South Africa
Broadwood Partners Comments on ISS Report on Proposed Sale of STAAR Surgical to Alcon - FinancialContent
Using the ICL as a supplementary IOL - EyeWorld
STAAR Surgical (STAA) Gains as ISS Backs Alcon's Improved Offer - GuruFocus
Battle for STAAR Surgical intensifies as Glass Lewis reiterates stance ’against’ - Investing.com Australia
Broadwood urges STAAR Surgical (NASDAQ: STAA) vote against Alcon sale - Stock Titan
Midday Stock Roundup: Rivian Rises on Chip, Models - Orange County Business Journal
STAAR Surgical (STAA) Faces Investor Pushback on Alcon Offer - GuruFocus
Glass Lewis Reaffirms its Recommendations to Shareholders of STAAR - marketscreener.com
Glass Lewis reaffirms opposition to Alcon’s STAAR acquisition bid - Investing.com
Glass Lewis reaffirms opposition to Alcon’s STAAR acquisition bid By Investing.com - Investing.com Australia
STAAR Surgical stock jumps 10% after Alcon sweetens buyout offer — investor says deal is 'worth substantially more' - MSN
STAAR Surgical accuses activist Broadwood of ’misinformation campaign’ - Investing.com
STAAR Surgical Rebuts Investor Claims Over Alcon Deal Process - Finimize
Why STAAR Surgical (STAA) Stock Is Up Today - Finviz
STAAR addresses activist investor claims about go-shop process By Investing.com - Investing.com Australia
STAAR Surgical (STAA): Assessing Valuation After Recent Share Price Weakness - Yahoo Finance UK
Broadwood continues opposition to STAAR’s acquisition by Alcon - Investing.com
Canaccord Genuity Raises Price Target for STAA, Reaffirms Hold R - GuruFocus
STAAR Surgical falls as Yunqi Capital reiterates opposition to merger with Alcon - Investing.com India
STAAR Surgical's Top Investors Reject Sweetened Alcon Offer, Cite Flawed Sale Process - Benzinga
STAAR Surgical (NASDAQ:STAA) Shares Gap DownWhat's Next? - MarketBeat
Alcon sweetens offer for Staar, major shareholders still unimpressed - BioWorld MedTech
Yunqi Capital Comments on STAAR Surgical?s Go-Shop Process - marketscreener.com
STAAR Surgical holder Yunqi Capital still against sale to Alcon (STAA:NASDAQ) - Seeking Alpha
STAAR Surgical Engages with its Employees - marketscreener.com
STAAR Surgical Acquisition by Alcon Opposed by Investor Yunqi Capital - marketscreener.com
Yunqi Capital opposes Alcon’s revised offer for STAAR Surgical - Investing.com
Yunqi Capital opposes Alcon’s revised offer for STAAR Surgical By Investing.com - Investing.com Australia
Yunqi Capital comments on Staar Surgical's go-shop process and Alcon's revised offer - marketscreener.com
Yunqi Capital Comments on STAAR Surgical’s Go-Shop Process and Alcon’s Revised Offer - marketscreener.com
Switzerland: Alcon agrees best and final offer with STAAR Surgical - Investors in Healthcare
Staar Surgical Co Stock (STAA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Staar Surgical Co Stock (STAA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BROADWOOD PARTNERS, L.P. | 10% Owner |
Nov 20 '25 |
Buy |
27.14 |
393,382 |
10,675,325 |
14,222,005 |
| BROADWOOD PARTNERS, L.P. | 10% Owner |
Nov 19 '25 |
Buy |
26.42 |
309,132 |
8,166,155 |
13,828,623 |
| Jiang Wei | Director |
Nov 12 '25 |
Option Exercise |
0.00 |
20,967 |
0 |
45,477 |
| Jiang Wei | Director |
Aug 12 '25 |
Option Exercise |
0.00 |
20,967 |
0 |
24,510 |
0.27%
0.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):